Intimation of closure of trading window of Jenburkt Pharmaceuticals Limited as per the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has informed the BSE that its trading window for designated persons, insiders, and their connected persons will remain closed from 1st January, 2026 until 48 hours after the company's standalone unaudited financial results for the quarter and nine months ending 31st December, 2025 are made public. The closure is being done as required under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company has also stated that it will separately notify the exchange about the date of the board meeting that will consider these Q3 results. The intimation has been signed by Ashish R. Shah, Sr. Vice President and Company Secretary.
This is a routine compliance filing and not material to the stock price. It signals that Q3 FY26 earnings are approaching, and insiders are barred from trading until the results are publicly disclosed, which is standard procedure before results announcements.